Herpes Zoster Ophthalmicus Clinical Presentation and Risk Factors for Loss of Vision

Am J Ophthalmol. 2021 Jun:226:83-89. doi: 10.1016/j.ajo.2021.02.002. Epub 2021 Feb 8.

Abstract

Purpose: To determine the rate of moderate and severe vision loss following herpes zoster ophthalmicus (HZO) and to identify associated factors.

Design: Retrospective cohort study.

Methods: All subjects with acute HZO seen at a single center from 2006 to 2016 were included in the study. The primary outcome measure was the proportion of individuals with moderate and/or severe loss of vision following an acute episode of HZO. Secondary outcome measures included causes and factors associated with permanent loss of vision owing to HZO.

Results: A total of 869 patients with acute HZO were identified with a median follow-up time of 6.3 years (interquartile range 3.7-8.9 years). Ocular involvement of HZO was diagnosed at or within the first month of presentation in 737 individuals (84.8%). The most common sites of ocular involvement were conjunctivitis (76.1%), followed by keratitis (51.2%) and uveitis (47.6%). Moderate vision loss (≤20/50) secondary to HZO occurred in 83 eyes (9.6%) while severe vision loss (≤20/200) occurred in 31 eyes (3.6%). Causes of loss of vision included corneal scarring (94.0%), corneal perforation (4.8%), and secondary glaucoma (1.2%). Severe vision loss was associated with older age (hazard ratio [HR] 1.059, P = .001), immunosuppression (HR 3.125, P = .028), poor presenting visual acuity (HR 2.821, P = .002), and uveitis (HR 4.777, P = .004) on multivariate analysis.

Conclusions: Among individuals with HZO, approximately 1 in 10 individuals may develop moderate or severe vision loss, primarily owing to corneal scarring. Older age, immunosuppression, and uveitis are associated with severe permanent loss of vision secondary to HZO.

MeSH terms

  • Acute Disease
  • Adolescent
  • Adult
  • Aged
  • Aged, 80 and over
  • Antiviral Agents / therapeutic use
  • Child
  • Child, Preschool
  • Female
  • Follow-Up Studies
  • Herpes Zoster Ophthalmicus / diagnosis*
  • Herpes Zoster Ophthalmicus / drug therapy
  • Herpes Zoster Ophthalmicus / epidemiology
  • Herpes Zoster Ophthalmicus / physiopathology
  • Humans
  • Immunosuppressive Agents / therapeutic use
  • Infant
  • Male
  • Middle Aged
  • Retrospective Studies
  • Risk Factors
  • Vision Disorders / diagnosis*
  • Vision Disorders / epidemiology
  • Vision Disorders / physiopathology
  • Visual Acuity / physiology

Substances

  • Antiviral Agents
  • Immunosuppressive Agents